2 results
Approved WMORecruiting
To reduce stent dysfunction after EUS-CDS by placing a FCSEMS through the LAMS, while maintaining effectiveness and safety of EUS-CDS as primary drainage strategy in patients with malignant distal biliary obstruction.
Approved WMORecruiting
To determine the immune-related progression free survival (irPFS) rate at 21 weeks and objective response rate (irORR) at 30 weeks in patients with pMMR CRC, dMMR mCRC, dMMR EC , dMMR SBC, dMMR SC treated with pembrolizumab combined with ataluren…